Can GLP-1 Weight Loss Drugs Protect the Heart?
On this episode of Health Matters, a cardiologist describes the ways that drugs developed for treating diabetes, and used for weight loss, impact cardiovascular health.
Health Matters · Faith Salie, Dr. David Majure
Audio is streamed directly from the publisher (p.podderapp.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
This week on Health Matters our host Faith Salie is joined by Dr. David Majure, Medical Director of the Heart Transplant Service with NewYork-Presbyterian and Weill Cornell Medicine, to discuss the use of GLP-1 drugs like Ozempic and WeGovy as a treatment to reduce the risk of cardiovascular death, heart attack, and stroke in certain adults. They explore the complex connections among weight, cardiovascular health, and inflammation, and how Dr. Majure uses GLP-1 drugs in his work with patients.
__
Health Matters was created to share the remarkable stories of science, care, and wellness that are happening every day at NewYork-Presbyterian, one of the nation’s most comprehensive healthcare delivery networks.
In keeping with NewYork-Presbyterian’s long history of medical excellence, Health Matters features the latest news and insights from our world-class physicians, nurses, and experts; inspiring first-hand accounts from patients and caregivers; and updates on the latest research and innovations in patient care, all in collaboration with our academic partners Columbia University Medical Center and Weill Cornell Medicine.
To learn more visit: